Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Sofosbuvir + Velpatasvir With or Without Ribavirin in Treatment-Naive Adults With Chronic HCV Infection

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 14.0

Eligibility Criteria:
Inclusion Criteria:~* Chronic HCV infection~* Body mass index (BMI) ≥ 18 kg/m\^2~* HCV RNA ≥ 10000 IU/mL at screening~* Use of highly effective contraception methods if female of childbearing potential or sexually active male~* Must not have cirrhosis~Exclusion Criteria:~* Current or prior history of clinically significant illness other than HCV~* Screening ECG with clinically significant abnormalities~* Prior exposure to HCV specific direct acting antiviral agent~* Prior treatment of HCV with interferon or ribavirin~* Pregnant or nursing female or male with pregnant female partner~* Chronic liver disease of non-HCV etiology~* Hepatitis B~* Active drug abuse~* Use of any prohibited concomitant medications

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- SOF+VEL 25 mg 12 Weeks (GT1) (Type: EXPERIMENTAL): Participants with genotype 1 HCV infection will receive SOF+VEL 25 mg for 12 weeks.
- SOF+VEL 100 mg 12 Weeks (GT1) (Type: EXPERIMENTAL): Participants with genotype 1 HCV infection will receive SOF+VEL 100 mg for 12 weeks.
- SOF+VEL 25 mg 12 Weeks (GT2/4/5/6) (Type: EXPERIMENTAL): Participants with genotype 2, 4, 5, or 6 HCV infection will receive SOF+VEL 25 mg for 12 weeks.
- SOF+VEL 100 mg 12 Weeks (GT2/4/5/6) (Type: EXPERIMENTAL): Participants with genotype 2, 4, 5, or 6 HCV infection will receive SOF+VEL 100 mg for 12 weeks.
- SOF+VEL 25 mg 12 Weeks (GT3) (Type: EXPERIMENTAL): Participants with genotype 3 HCV infection will receive SOF+VEL 25 mg for 12 weeks.
- SOF+VEL 100 mg 12 Weeks (GT3) (Type: EXPERIMENTAL): Participants with genotype 3 HCV infection will receive SOF+VEL 100 mg for 12 weeks.
- SOF+VEL 25 mg 8 Weeks (GT1) (Type: EXPERIMENTAL): Participants with genotype 1 HCV infection will receive SOF+VEL 25 mg for 8 weeks.
- SOF+VEL 25 mg + RBV 8 Weeks (GT1) (Type: EXPERIMENTAL): Participants with genotype 1 HCV infection will receive SOF+VEL 25 mg plus RBV for 8 weeks.
- SOF+VEL 100 mg 8 Weeks (GT1) (Type: EXPERIMENTAL): Participants with genotype 1 HCV infection will receive SOF+VEL 100 mg for 8 weeks.
- SOF+VEL 100 mg + RBV 8 Weeks (GT1) (Type: EXPERIMENTAL): Participants with genotype 1 HCV infection will receive SOF+VEL 100 mg plus RBV for 8 weeks.
- SOF+VEL 25 mg 8 Weeks (GT2) (Type: EXPERIMENTAL): Participants with genotype 2 HCV infection will receive SOF+VEL 25 mg for 8 weeks.
- SOF+VEL 25 mg + RBV 8 Weeks (GT2) (Type: EXPERIMENTAL): Participants with genotype 2 HCV infection will receive SOF+VEL 25 mg plus RBV for 8 weeks.
- SOF+VEL 100 mg 8 Weeks (GT2) (Type: EXPERIMENTAL): Participants with genotype 2 HCV infection will receive SOF+VEL 100 mg for 8 weeks.
- SOF+VEL 100 mg + RBV 8 Weeks (GT2) (Type: EXPERIMENTAL): Participants with genotype 2 HCV infection will receive SOF+VEL 100 mg plus RBV for 8 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete